Treatment of skin papillomas with topical alpha-lactalbumin-oleic acid.
Lotta Gustafsson, Irene Leijonhufvud, Annika Aronsson...
https://pubmed.ncbi.nlm.nih.gov/15215482/Actively Recruiting
Led by KTH Biopharma · Updated on 2026-10-20
70
Participants Needed
1
Research Sites
4 weeks
Total Duration
Researchers are conducting a Phase II randomized, double-blind, placebo-controlled clinical trial to evaluate the effectiveness and recurrence of genital warts using a combination of CO2 laser treatment and Geniwa gel compared to CO2 laser combined with a placebo gel. This study involves 60 to 80 patients with recurrent genital warts resistant to conventional treatments. It aims to assess whether adding Geniwa gel improves outcomes over placebo gel when used with CO2 laser therapy. Participants are randomly assigned to two groups one group receives CO2 laser treatment followed by Geniwa gel application, and the other group receives CO2 laser followed by a placebo gel. Treatment lasts for 6 weeks, with gel applied to lesions daily under a hydrocolloid dressing. If warts recur during this period, CO2 laser treatment is reapplied followed by continued gel use. After the initial 6 weeks, all participants are offered a 6-week open-label phase with Geniwa gel. Additional standard treatments may be used after the study. Antibiotics and a topical gel are prescribed to reduce infection and promote healing alongside study treatments. Participants undergo inspections, measurements, and photographs of lesions at enrollment, throughout weeks 2 to 12 during treatment, and again 3 to 6 months after treatment completion. The volume and size of warts are monitored. Safety is assessed throughout the treatment period. A follow-up visit occurs 4 to 6 months after the second treatment phase to check for new or recurring lesions and to gather patient-reported outcomes about lesion resolution and any other treatments used. Total participation spans several months including treatment and follow-up.
CONDITIONS
Treatment of Recurrent Genital Warts by Combination of CO2 Laser and Geniwa Gel
T
Thanh Tam Tran, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
KTH Biopharma
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 6 weeks
Participants receive CO2 laser treatment followed by daily application of either Geniwa gel or placebo gel for 6 weeks. Lesions are covered with a dressing overnight and patients apply gel at home daily. If warts recur, CO2 laser treatment is repeated with continued gel use.
Weekly visits to receive gel and monitor lesions
Duration - 6 weeks
All participants are offered an additional 6 weeks of treatment with Geniwa gel without knowing their initial assignment. They follow the same gel application and monitoring procedures as in the first phase.
Weekly visits for gel supply and lesion assessment
Duration - 4 to 6 months
Participants return for evaluation of lesion sites and any new warts 4 to 6 months after the last treatment. They are interviewed about lesion resolution and any additional treatments or illnesses since then.
1 to 2 follow-up visits
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Lotta Gustafsson, Irene Leijonhufvud, Annika Aronsson...
https://pubmed.ncbi.nlm.nih.gov/15215482/KTH Biopharma
Lead Sponsor